Introduction
The cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-regulated chloride channel expressed in the apical plasma membrane of airway, intestinal, pancreatic, and other epithelia. CFTR has cytoplasmic amino-and carboxy-termini and contains two membrane-spanning domains (MSD1 and MSD2), each of which is associated with a nucleotide binding domain (NBD1 and NBD2). The MSD1-NBD1 and MSD2-NBD2 domains are linked by a regulatory domain that can be phosphorylated.
1,2 Deletion of phenylalanine 508 (∆F508) in the NBD1 domain is the most common CFTR mutation causing cystic fibrosis. 3 The ∆F508 mutation causes focal and global CFTR misfolding that results in endoplasmic reticulum retention, accelerated degradation, and impaired chloride channel function. 4 The ∆F508 mutation destabilizes the NBD1 domain of CFTR both thermodynamically and kinetically. [5] [6] [7] Suppressor mutations, such as R1S (G550E, R553Q, R555K, and F494N), structural defects-defective ∆F508-NBD1 stability and the NBD-MSD interfacial defect-might rescue ∆F508-CFTR function to near wild-type levels. 9 Whereas specific modulators have been identified that target NBD1-MSD interfacial defects, such as VX-809, there are no small molecules that selectively improve ∆F508-NBD1 stability. The robust ∆F508-CFTR correction achieved using VX-809, together with chemical chaperones, such as glycerol and myo-inositol, or second-site suppressor mutations that stabilize ∆F508-NBD1, 9 offers further rationale to identify NBD1-targeted CFTR modulators.
The objective of this study was to develop a screen to identify ∆F508-NBD1-targeted modulators. A domain-selective screen was implemented in which the ∆F508-NBD1 domain of human CFTR was linked to the single MSD of CD4 and an extracellular horseradish peroxidase (HRP) tag (Fig. 1A) . Small molecules targeting ∆F508-NBD1 might rescue ∆F508-CFTR misfolding and/or function by direct interaction or indirect proteostasis mechanisms.
Materials and Methods

Chemicals and Compounds
VX-809, VX-661, VX-770, and CFTR inh -172 were purchased from Selleck Chemicals (Boston, MA). Correctors C3, C4, and C18 were obtained from the CFTR Compound Program, Cystic Fibrosis Foundation Therapeutics Inc., which is administered at Rosalind Franklin University of Medicine and Science; CoPo-22, PG-01, and WX corr -A23 were obtained from an in-house repository of CFTR modulators. Bromoindole-acetic acid (BIA) was purchased from Santa Cruz Biotechnology (Dallas, TX). For screening, approximately 20,000 diverse drug-like synthetic compounds (>90% with molecular size 250-500 Da; ChemDiv Inc., San Diego, CA) were tested. One hundred and twenty commercially available carboxamide-benzothiophene analogs were purchased from ChemDiv for structure-activity studies.
Cell Lines
Doxycycline-inducible expression systems were generated by lentiviral transduction as described.
10 CD4TM-NBD1 expression constructs were generated by insertion of PCRamplified NBD1 cDNA containing the 1S mutation into XmaI/ApaI sites of pcDNA3-CD4T. 11 For expression of extracellular HRP-tagged CD4TM-∆F508-NBD1-1S chimeras, the extracellular CD4 domain of previously described CD4T-∆F508-NBD1-1S 8 was replaced in-frame with the catalytic domain of HRP. Madin-Darby canine kidney type II (MDCK) cells were transduced with lentivirus, and for each construct, >40 single clones were screened to identify clones with high expression and signal-to-background ratio. MDCK cells expressing HRP-CD4TM-∆F508-NBD1-1S (HRP-∆F508-NBD1) and HRP-CD4TM-WT-NBD1-1S (HRPwild-type-NBD1) were grown at 37 °C and maintained in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) under puromycin (3 μg/mL) and G418 (0.2 mg/mL) selection. For low-temperature rescue experiments, cells were grown to 90%-100% confluence at 37 °C and then maintained at 27 °C for 18-24 h.
Fisher rat thyroid (FRT) epithelial cells stably expressing ∆F508, G551D, or wild-type CFTR were used as described. 12 FRT cells were cultured in Coon's modified Ham's F-12 medium supplemented with 10% FBS, 2 mM l-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. CFBE41o-TetON (CFBE) cells expressing ∆F508-CFTR-HRP were used as described. 10, 13 CFBE cells were grown in minimal essential medium supplemented with 10% FBS, 2 mM l-glutamine, and 10 mM HEPES.
Screening
For screening, MDCK cells were plated in black, 96-well microplates (Costar; Corning Inc., Tewksbury, MA) at 10,000 cells/well. MDCK cells (passages 2-5) were grown to confluency before plating. HRP-∆F508-NBD1 expression was induced 24 h after plating with 0.5 μg/mL doxycycline for 2 days before screening. Screening was performed using a Beckman Coulter (Fullerton, CA) Biomek FX platform. MDCK cells expressing HRP-∆F508-NBD1 were incubated with 100 μL of medium containing 25 μM test compound and 0.5 μg/mL doxycycline for 24 h at 37 °C. All compound plates contained negative controls (DMSO vehicle) and positive controls (MDCK cells expressing HRPwild-type-NBD1). The cells were washed four times with phosphate-buffered saline (PBS), and HRP activity was assayed by the addition of 50 μL/well of HRP substrate (WesternBright Sirius Kit; Advansta Corp., Menlo Park, CA). After shaking for 5 min, chemiluminescence was measured using a Tecan Infinite M1000 plate reader (Tecan Groups Ltd., Mannedorf, Switzerland) equipped with an automated stacker. The Z′ factor was computed as 1 − [(3 × standard deviation of maximum signal control + 3 × standard deviation of minimum signal control)/absolute (mean of maximum signal control − mean of minimum signal control)]. A Z′ factor >0.5 is considered a robust assay.
Short-Circuit Current
Short-circuit current in cells expressing full-length ∆F508-CFTR was measured as described. 12 For the corrector assay, FRT cells expressing ∆F508-CFTR were cultured on inserts (Snapwell; Corning) for 5-7 days and then incubated with test compounds (with or without 3 μM VX-809) for 18-24 h at 37 °C before measurements. For the potentiator assay, 3 μM VX-809 was added for 18-24 h at 37 °C before measurements. The basolateral solution contained 120 mM NaCl, 3 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM glucose, 25 mM NaHCO 3 , and 5 mM HEPES, pH 7.4. In the apical bathing solution, 60 mM NaCl was replaced by Na gluconate and CaCl 2 was increased to 2 mM. Solutions were bubbled with 95% O 2 /5% CO 2 and maintained at 37 °C. The basolateral membrane was permeabilized with 250 μg/mL amphotericin B. Hemichambers were connected to a DVC-1000 voltage clamp (World Precision Instruments Inc., Sarasota, FL) via Ag/AgCl electrodes and 1 M KCl agar bridges.
CFTR Plasma Membrane Expression
∆F508-CFTR cell surface expression was measured as described.
14 Briefly, ∆F508-CFTR-HRP expression in CFBE cells was induced after 24 h with 0.5 μg/mL doxycycline for 2 days before assay. Cells were incubated with test compound (20 μM) and 0.5 μg/mL doxycycline for 24 h at 37 °C. Plates contained negative controls (DMSO vehicle) and positive controls (3 μM VX-809). Cells were washed, HRP substrate was added, and luminescence (reported as relative luminescence units) was measured.
Differential Scanning Fluorimetry
Recombinant human ∆F508-NBD1 containing a single suppressor mutation (1S; F494N) was purified, and melting temperature measurement was done as described. 8 Differential scanning fluorometry of ∆F508-NBD1 (6 μM) was done in 150 mM NaCl, 20 mM MgCl 2 , 10 mM HEPES, and 2.5 mM ATP, pH 7.5, using a Stratagene Mx3005p (Agilent Technologies, La Jolla, CA) quantitative PCR instrument in the presence of 2× Sypro Orange.
Immunoblotting
Immunoblotting was done using standard procedures. 8 The HRP-CD4TM-NBD1-1S constructs were detected with mouse monoclonal anti-hemagglutinin (HA) antibody (Covance) with anti-tubulin antibody as the loading control.
Statistics
Statistical analysis was done using the Prism 5 GraphPad Software package (San Diego, CA). Data are presented as the mean ± standard error of the mean (SEM), and statistical significance was set at p < 0.05.
Results
Screen for NBD1-Targeted Modulators of ΔF508-CFTR
The assay used a chimeric transmembrane reporter consisting of NBD1 linked to the single transmembrane helix of CD4 and an extracellular reporter to provide a readout of cell surface presentation. As shown in Figure 1A , human wild-type and ∆F508 NBD1 domains (amino acids 389-679) carrying the single 1S (F494N) mutation that stabilizes NBD1 were linked at their C-termini to the CD4 transmembrane domain, and a HRP isoenzyme C moiety was linked at the endoplasmic reticulum lumen/extracellular end of the CD4 transmembrane domain to report cell surface presentation. In addition, a single HA tag was incorporated to facilitate detection by immunoblot. The MDCK cells used for HTS were engineered using a doxycycline transactivator-inducible expression system to control HRP-CD4TM-NBD1-1S levels as described. 10 By immunoblot (Fig. 1B) , HRP-CD4TM-WT-NBD1-1S (HRP-wild-type-NBD1) or HRP-CD4TM-∆F508-NBD1-1 (HRP-∆F508-NBD1) protein was not seen without doxycycline induction. With doxycycline, significantly greater HRP-wild-type-NBD1 expression was observed than HRP-∆F508-NBD1, consistent with misfolding and degradation of the ∆F508-NBD1 reporter. The rationale of the screen is that compounds that interact with the ∆F508-NBD1 protein and correct its folding defect will permit accumulation at the plasma membrane.
MDCK cells expressing the HRP-∆F508-NBD1 and HRP-wild-type-NBD1 chimeras were assayed for cell surface HRP activity (Fig. 1C) . Minimal HRP activity was seen without doxycycline induction; doxycycline induction produced somewhat greater activity in cells expressing the ∆F508-NBD1 reporter, and much greater activity for cells expressing the wild-type NBD1 reporter. Chemical chaperones, including myo-inositol, glycerol, and trimethylamine oxide (TMAO), which increase the thermal stability of the ∆F508-NBD1 domain in vitro, 10 did not increase the HRP signal. However, low temperature (27 °C) incubation strongly increased the HRP signal. BIA, a reported lowaffinity ∆F508-NBD1 binder, 15 did not increase the HRP signal. Also, a panel of known CFTR modulators was tested, including correctors VX-809, VX-661, C3, and C18, which target the NBD1-MSD interface, 9 C4, which targets NBD2, 16 CoPo-22, a CFTR modulator with dual corrector and potentiator function, 12 and W1282X corr -A23, which corrects CFTR 1281 , the protein product generated by the W1282X-CFTR nonsense mutation. 17 None of these correctors increased ∆F508-NBD1 cell surface expression; nor did previously described potentiators VX-770 and PG-01.
High-throughput screening was done in order to identify NBD1 modulators. Figure 2A diagrams the screening approach in which small molecules were tested for rescue of defective ∆F508-NBD1 folding/trafficking. Primary screening was done in 96-well plates in which MDCK cells expressing HRP-∆F508-NBD1 were induced with doxycycline 48 h prior to screening, with test compounds incubated at 25 μM for 24 h prior to HRP assay. The screen was robust with a Z′ factor of 0.7. Figure 2B shows a scatterplot of the original HRP luminescence data for each of the compounds tested, along with the positive control (MDCK cells expressing HRP-wild-type-NBD1). Figure 2C shows the chemical structures of four active compounds (A-01, B-01, C-01, and D-01) that were verified on retesting. Scaffolds A-01, B-01, C-01, and D-01 include a carboxamide-benzothiophene, pyrazolo-diazepine, dioxino-benzimidazole, and triazolooxazine, respectively. These scaffolds are distinct from known ∆F508-CFTR correctors and potentiators.
Compound Action on Full-Length ΔF508-CFTR
Compound effects on the function of full-length ∆F508-CFTR were studied by short-circuit current in FRT cells expressing ∆F508-CFTR. The apical membrane chloride current was measured in the presence of a transepithelial chloride gradient and after basolateral membrane permeabilization, so that current provides a quantitative, linear measure of CFTR chloride conductance. Compounds B-01, C-01, and D-01 did not change chloride conductance, either alone or when added for 24 h together with 3 μM VX-809 (data not shown). Compound A-01, when added alone, did not change chloride conductance (short-circuit current 14 ± 4 μA/cm 2 and 12 ± 5 μA/cm 2 for 20 μM A-01 vs control, respectively). However, as shown in Figure 3A , A-01 together with 3 μM VX-809 increased the response to forskolin significantly greater than that of VX-809 alone (43 ± 5 μA/cm 2 vs 29 ± 3 μA/cm 2 , respectively), though it did not increase maximal chloride conductance after addition of potentiator VX-770. The increase in the forskolin response to A-01 could represent potentiator and/or corrector actions. To investigate possible potentiator activity, compounds were added acutely to cells in which ∆F508-CFTR cell surface expression was rescued by low-temperature (27 °C) incubation. Following the addition of forskolin, compound A-01 increased chloride current in a concentrationdependent manner with a low micromolar EC 50 and maximal current (at 30 μM A-01) that was ~50% of that produced by VX-770. Similar studies done for compounds B-01, C-01, and D-01 did not show potentiator activity (data not shown). To investigate possible corrector activity, compounds at 20 μM were incubated with CFBE41o-cells expressing ∆F508-CFTR with HRP engineered into the fourth extracellular loop (to report cell surface expression) for 24 h, and then cell surface HRP activity was assayed (Fig. 3C) . None of the compound, when added alone, produced a signal increase. Though a substantial increase in HRP signal was produced by VX-809, no further signal increase was found when a test compound was included with VX-809. These results suggest that compound A-01 has ∆F508-CFTR potentiator but not corrector activity.
Compound A-01 was also tested for potentiator activity in FRT cells expressing wild-type CFTR (Fig. 3D) . A low concentration of forskolin (25 nM) was added prior to the addition of A-01 to produce a low basal level of CFTR activation. Maximal forskolin (20 μM) was added after A-01 to fully activate wild-type CFTR. A-01 at a high concentration of 30 μM produced minimal (~8%) activation of wild-type CFTR. A-01 was also tested in FRT cells expressing G551D-CFTR, a gating mutant that produces little chloride current with maximal forskolin (Fig. 3E) ; A-01 did not activate G551D-CFTR at high concentration, with VX-770 shown as the positive control. The results suggest that A-01 is a selective ∆F508-CFTR potentiator. 
Structure-Activity Analysis of CarboxamideBenzothiophenes
One hundred and twenty commercially available A-01 analogs were tested in MDCK cells expressing HRP-∆F508-NBD1. Three additional carboxamide-benzothiophenes (A-02, A-03, and A-04) showed activity, with 2.4-, 2.0-, and 1.7-fold increased luminescence signal, respectively, over the control, DMSO-treated cells. Figure 4A (left) shows concentration dependence data. The structures of A-02, A-03, and A-04 were similar to that of A-01 (Fig. 4A right) . Compounds were also assayed by short-circuit current for ∆F508-CFTR potentiator activity (Fig. 4B) . All three analogs showed activity. Though all four carboxamide-benzothiophenes showed activity in the ∆F508-NBD1 assay (Fig.  4A) and the ∆F508-CFTR potentiator assay (Fig. 4B) , the relative activities did not correlate (Fig. 4C) .
Last, the compounds were tested for direct thermostabilization of ∆F508-NBD1-1S, based on melting temperature determination monitored by differential scanning fluorometry. As shown in Figure 4D left, compound A-01 did not alter NBD1-1S melting curves, whereas 5% glycerol (positive control) right-shifted the melting curves as reported before. 9 None of the other compounds identified in this screen, including active analogs of A-01, altered NBD1-1S melting temperature, as shown in the data summary (Fig.  4D right) . Table 1 summarizes the activity of selected compounds in the various assays.
Discussion
The motivation for the screen developed here is the prediction that correction of defects in both ∆F508-NBD1 energetics and the NBD1-MSD interface may effectively rescue the defective folding and processing of full-length ∆F508-CFTR. 8 While certain clinical and investigational correctors, including VX-809, C3, and C18, target the NBD1-MSD interfacial defects, no modulators identified to date selectively target ∆F508-NBD1. Herein, we implemented a cell-based biochemical screen to identify NBD1-targeted modulators using a chimera of the human ∆F508-NBD1 domain fused with the single transmembrane domain of CD4 containing an extracellular HRP tag. A panel of known CFTR modulators, including the correctors VX-809 and C4 (targeting the NBD2 domain), did not increase ∆F508-NBD1 cell surface expression as anticipated because these compounds act on other regions of ∆F508-CFTR. The compound BIA, which was shown to bind NBD1 protein in cocrystallization studies and to stabilize ∆F508-NBD1 energetics and enhance ∆F508-CFTR protein maturation in fibroblast cell models, 15 was not active in the ∆F508-NBD1 assay.
The screen identified four compounds that increased ∆F508-NBD1 cell surface expression. Though the compounds did not show corrector activity in cells expressing full-length ∆F508-CFTR, one of the compounds was found to have potentiator activity. The compound, A-01, a carboxamide-benzothiophene, is chemically different from previously described ∆F508-CFTR modulators. Melting temperature shift studies showed that A-01 did not produce ∆F508-NBD1 domain thermostabilization. In prior studies, some correctors, including C6 and C12, produced ∆F508-NBD1 thermostabilization, as did chemical chaperones, including glycerol and TMAO. 9 The in vitro domain thermostabilization assay might not correlate well with stabilizing efficacy in the context of full-length ∆F508-CFTR.
It was remarkable that A-01, a compound identified from the ∆F508-NBD1 cell surface presentation screen, had potentiator activity when tested on full-length ∆F508-CFTR. However, none of the active compounds identified in the domain screen of 20,000 small molecules functioned as correctors of full-length ∆F508-CFTR, though it is possible that a larger screen might produce correctors. We speculate that conformational changes induced by A-01 on the ∆F508-NBD1 domain in isolation are sufficient to partially rescue its defective trafficking, but not sufficient to rescue defective cellular processing of full-length ∆F508-CFTR, in which the NBD1 structural alterations are ineffective or its binding sites are not accessible. Modulators identified in the screen might also rescue ∆F508-NBD1 cell surface presentation indirectly as proteostasis regulators by modulating the cellular machinery responsible for its folding, degradation, and vesicular trafficking. However, such indirect mechanisms might not translate into compound efficacy as correctors of full-length ∆F508-CFTR. Previous studies have suggested that isolated NBD1 might not contain the necessary structural features to support highaffinity interactions. 18 Another interesting finding was that A-01 acted as a potentiator of full-length ∆F508-CFTR but not of wild-type CFTR or G551D-CFTR. Generally, CFTR modulators identified for a specific mutant have demonstrated promiscuity toward other cystic fibrosis-causing CFTR mutants. Though VX-770 is a potentiator for G551D-CFTR, 19 it has now been approved for >20 Class III gating mutants, certain splicing mutations, 20 and in combination with VX-809, for the ∆F508-CFTR Class II mutation. VX-809 and VX-770, as well as several additional investigational correctors and potentiators, showed efficacy for the truncation product CFTR 1281 generated by the W1282X-CFTR premature termination codon. 17 The apparent selectivity of A-01 for ∆F508-CFTR could be due to its specific interaction with the ∆F508-NBD1 topological and electrostatic surfaces not found in wild-type CFTR or G551D-CFTR.
Screening to identify ∆F508-CFTR modulators has generally relied on heterologous systems expressing full-length ∆F508-CFTR constructs and functional assessment of activity using fluorescent potentiometric or halide sensors. 16, 19, 21, 22 These studies identified C4 (corr-4a), the first corrector of ∆F508-CFTR, 16 as well as VX-809. 23 More recently, potentiometric sensors have also been used in Melting temperature measurement assay using recombinant ∆F508-NBD1.
human airway epithelial cell cultures to test CFTR modulators against ∆F508-CFTR and other CFTR mutations. 24, 25 A biochemical synergy screen of ∆F508-CFTR surface expression was developed using an engineered extracellular epitope 14 to discover second-generation corrector combinations that target distinct ∆F508-CFTR folding defects. Novel ∆F508-CFTR therapeutics with two correctors and a potentiator are in clinical development. 26 High-content screening approaches have recently been developed using dual-tagged ∆F508-CFTR with an amino-terminus mCherry and an extracellular epitope tag for ratiometric determination of surface presentation. 27 Structure-based virtual screening has also been used to identify small molecules that inhibit keratin 8-∆F508-CFTR interactions and mediate ∆F508-CFTR rescue in cell models. 28 Assays of folding/ solubility of CFTR NBD1 domains have been developed that rely on structural complementation of isolated domains from enzymes such as β-galactosidase, 29, 30 although to the best of our knowledge such assays have not been applied to the identification of CFTR modulators.
A few biological activities have been reported for the carboxamide-benzothiophene scaffold identified in this study. Carboxamide-benzothiophenes were shown to have antimalarial activity targeting the N-myristoyltransferase of Plasmodium falciparum and Plasmodium vivax. 31 Carboxamide-benzothiophenes were also found to decrease the adherence of neutrophils to activated endothelial cells by inhibiting upregulation of the adhesion proteins E-selectin, ICAM-1, and VCAM-1. 32 Compound A-01 has drug-like properties, including favorable molecular weight (391 Da), topological polar surface area (57 Å 2 ), and cLogP (4.8).
In summary, the results here provide a proof of concept for NBD1 domain-targeted screening to identify ∆F508-NBD1 modulators. Additional screening, together with structural optimization, might produce more efficacious ∆F508-NBD1 modulators that act in synergy with ∆F508-CFTR modulators acting at other sites.
